
Véronique Moulin
Chercheuse universitaire
Axe Médecine régénératrice
HEJ
R-225
Québec, Québec
Canada G1J 1Z4
Full professor
Department of Surgery
Faculty of Medicine
Following her training in France, in Paris, Dr. Moulin was recruited to better understand the complex process of healing. Since 1998, she has been a professor at Université Laval, Faculty of Medicine, Department of Surgery but also a researcher at the LOEX Center at Université Laval and at the Research Center of the CHU de Quebec. Her work focuses on the normal and pathological mechanisms of skin healing. To perform this, she uses different cell culture models reconstituted by tissue engineering to reproduce in vitro fibrotic skin diseases (hypertrophic scars, scleroderma). At the same time, she uses the tissue engineering method to reconstruct cutaneous substitutes to treat skin deficient patients, after burns, for example.
Myofibroblasts in normal or pathological scars: These cells appear during wound healing and play an important role in the contraction of the edges of the wound. Dr. Moulin’s team has shown that these cells also play a central role in the production of extracellular matrix as well as in angiogenesis. They also have a role in the formation of disabling scars such as hypertrophic scars. Dr. Moulin’s team analyzes the different functions of myofibroblasts in normal or pathological scarring; investigates existing interactions between endothelial cells, keratinocytes, fibroblasts, and myofibroblasts; and analyzes the role of extracellular matrix secreted by cells in various cellular functions such as apoptosis, angiogenesis, or cell differentiation.
Systemic scleroderma: This pathology is a fibrotic disease that stiffens all organs, including the skin, and is fatal in the long term. Dr. Moulin uses the method of tissue engineering to understand this pathology but especially to determine new treatments to reduce fibrosis.
Clinical application of tissue engineering: Tissue engineering skin production is carried out from patients’ cells and then grafted onto them to allow closure of wounds in patients unable to heal after extensive burns or other pathologies. The properties of skin reconstructed by our method are being evaluated in a clinical trial accepted by Health Canada to cover large burned patients.
Team
Élodie Mareux
Stagiaire postdoctorale
Louise Bossé
Employé
Véronique Germain
Employée
HEJ
1401 18e RueQuébec, QC
Canada G1J 1Z4 +1 418 990-8251 +1 418 990-8255, poste 61715 veronique.germain@crchudequebec.ulaval.ca
Martin Barbier
Employé
Felicie Camus
Stagiaire
Nataliia Pavlenko
Employée
Marie-Ève Laroche
Employée
Friederike Pfau
Employée
HEJ
1401, 18e RueLOEX / CMDGT
R-125
Québec, Québec
Canada G1J 1Z4 +1 418 525-4444, poste 61685 Friederike.Pfau@crchudequebec.ulaval.ca
Elias Cuartas-Gomez
Employé
Manon Labrecque
Employée
HEJ
1401, 18e RueR-121
Québec, Québec
Canada G1J 1Z4 +1 418 990-8255, poste 61661 Manon.Labrecque@crchudequebec.ulaval.ca
ElHadji Mouhamadou Sakhir Djite
Employé
HEJ
1401, 18e rueQuébec, QC
Canada G1J 1Z4 +1 418 525-4444 elhadji-mouhomadou-sakhir.djite@crchudequebec.ulaval.ca
Marie-Hélène Lavoie-Pelletier
Employée
Sébastien Larochelle
Employé
HEJ
1401, 18e RueR-118
Québec, Québec
Canada G1J 1Z4 +1 418 990-8248 +1 418 990-8255, poste 61679 Sebastien.Larochelle@crchudequebec.ulaval.ca
Bettina Cattier
Employée
Cindy Jean Hayward de Mendoza
Employée
Andréa Tremblay
Employée
Emilie Genin
Employée
Oumayma Hayouni
Employée
Anabelle Demers
Employée
HEJ
1401 18e RueR-107
Québec, QC
Canada G1J 1Z4 +1 418 990-8251 +1 418 990-8255, poste 61715 anabelle.demers@crchudequebec.ulaval.ca Anabelle.Demers@USherbrooke.ca
Geneviève Bernard
Employée
HEJ
1401, 18e RueQuébec, Québec
Canada G1J 1Z4 +1 418 990-8248 +1 418 990-8255, poste 61679 Genevieve.Bernard@crchudequebec.ulaval.ca
Karel Ferland
Employée
HEJ
1401 18e RueR-119, LOEX/ CMDGT
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, poste 61680 karel.ferland@crchudequebec.ulaval.ca
Chantal Fauvel
Employée
HEJ
1401, 18e RueR-118
Québec, Québec
Canada G1J 1Z4 +1 418 525-4444, poste 61679 chantal.fauvel@crchudequebec.ulaval.ca
Publications
View all-
article Arif S, Richer M, Larochelle S, Moulin VJ
Microvesicles derived from dermal myofibroblasts modify the integrity of the blood and lymphatic barriers using distinct endocytosis pathways
J Extracell Biol 3 (5), 2024.
-
article Arif S, Moulin VJ
Extracellular vesicles on the move: Traversing the complex matrix of tissues
Eur J Cell Biol 102 (4), 2023.
-
article Moulin VJ
Three-Dimensional Model of Hypertrophic Scar Using a Tissue-Engineering Approach
Methods Mol Biol 2299 2021.
Projects
- A cGMP facility for personalized tissue engineering, from 2024-12-01 to 2027-12-31
- Tissue engineering to treat Canadian burn patients: the Self-Assembled Skin Substitutes (SASS), from 2022-04-01 to 2026-01-31
- The implication of PlGF in cutaneous fibrosis, from 2022-10-01 to 2027-09-30
- Allogeneic dermis to accelerate the production of a tissue-engineered skin substitute to treat Canadian burn patients, from 2023-04-01 to 2025-07-31
- Real World Clinical and Economic Burden of Severe Burn Injuries, from 2023-10-01 to 2026-09-30
- Clinical trial for dystrophic epidermolysis bullosa (EB) using GMEB-SASS, a genetically modified EB skin substitute, from 2025-04-01 to 2028-03-31
- Toward a combined gene therapy and tissue engineering novel treatment for junctional epidermolysis bullosa, from 2025-04-01 to 2028-03-31
- Blood versus lymphatic endothelial cells: different responses for different roles, from 2025-04-01 to 2030-03-31
- Mise au point par génie tissulaire d'un modèle de cicatrisation cutanée contenant des cellules immunitaires, from 2019-01-27 to 2024-02-29
- Action des microvésicules dans les tissus solides, from 2019-04-01 to 2025-03-31
- Centre du génie tissulaire (CHU de Québec - Université Laval), from 2019-04-01 to 2025-03-31
- Combining tissue-engineered skin with ex vivo gene therapy correction to develop a treatment for epidermolysis bullosa, from 2022-04-01 to 2025-01-31
- Cryo-TEM infrastructure for the visualisation of nanoparticles, exosomes and virus-like particles, from 2023-03-31 to 2024-03-31
- Setting up the conditions for the biobanking of tissues and cells from hypertrophic scars, from 2022-12-01 to 2024-02-28